Revance Therapeutics (RVNC) Earns News Impact Score of 0.16
Media stories about Revance Therapeutics (NASDAQ:RVNC) have been trending somewhat positive on Sunday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Revance Therapeutics earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.0119632946132 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Revance Therapeutics, Inc. (RVNC) CEO Sells $179,208.00 in Stock (americanbankingnews.com)
- Revance Therapeutics : to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference (4-traders.com)
- Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference (finance.yahoo.com)
- ETFs with exposure to Revance Therapeutics, Inc. : September 19, 2017 (finance.yahoo.com)
- Revance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 (finance.yahoo.com)
Revance Therapeutics (RVNC) opened at 24.10 on Friday. The stock’s market cap is $742.74 million. Revance Therapeutics has a 52 week low of $12.35 and a 52 week high of $28.30. The stock has a 50 day moving average of $23.75 and a 200-day moving average of $22.58.
Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.93) by $0.03. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. Revance Therapeutics had a negative net margin of 32,936.67% and a negative return on equity of 55.21%. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.88) earnings per share. Analysts forecast that Revance Therapeutics will post ($3.77) earnings per share for the current year.
A number of equities analysts have weighed in on RVNC shares. Cantor Fitzgerald started coverage on shares of Revance Therapeutics in a research note on Thursday, July 20th. They set an “overweight” rating and a $50.00 price target on the stock. BidaskClub downgraded shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Zacks Investment Research downgraded shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, September 7th. Aegis reaffirmed a “buy” rating and set a $36.00 price target on shares of Revance Therapeutics in a research note on Thursday, June 8th. Finally, ValuEngine raised shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 9th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $35.20.
In other Revance Therapeutics news, CEO L Daniel Browne sold 7,600 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $23.58, for a total value of $179,208.00. Following the completion of the sale, the chief executive officer now directly owns 148,450 shares of the company’s stock, valued at $3,500,451. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 18.86% of the company’s stock.
About Revance Therapeutics
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.